Results 181 to 190 of about 247,651 (343)

GOES GLM, biased bolides, and debiased distributions

open access: hybrid, 2023
Anthony Ozerov   +4 more
openalex   +1 more source

Time‐Continuous Prognostic Mapping of Bell's Palsy Using Yanagihara Scores and Electroneurography

open access: yesThe Laryngoscope, EarlyView.
This study developed a novel, time‐continuous prognostic mapping for Bell's palsy by integrating longitudinal Yanagihara scores and electroneurography in patients treated with high‐dose corticosteroids. By employing a Bayesian probabilistic approach, this model enables individualized recovery estimation at any clinical time point, overcoming the ...
Shogo N. Watanabe   +4 more
wiley   +1 more source

gôlēm, √glm, gelôm

open access: yes, 2022
Riesame dell'uso e del significato della parola golem in Salmi 139:16, e della radice *glm nei passi collegati.
openaire   +1 more source

Underground Lag: Fungal Community and Edaphic Legacies After Disturbance

open access: yesLand Degradation &Development, EarlyView.
ABSTRACT Páramos are neotropical mountain ecosystems that regulate water and store large amounts of carbon, but are increasingly degraded by agriculture and grazing. Although native vegetation often recolonizes after abandonment, belowground recovery remains poorly understood.
Wilmer Dajhan Navarrete‐López   +6 more
wiley   +1 more source

Treatment Continuation and Long‐Term Outcomes of Perampanel in Primary Orthostatic Tremor; A Cohort Study

open access: yesMovement Disorders Clinical Practice, EarlyView.
Background Primary orthostatic tremor (POT) is a rare hyperkinetic movement disorder with limited and largely ineffective treatment options. Perampanel has been suggested as a therapy, but has so far only been investigated in small studies with short duration.
Wietske A. Babeliowsky   +4 more
wiley   +1 more source

Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Leucine‐rich repeat kinase 2 (LRRK2) kinase inhibition is a promising therapeutic strategy for Parkinson's disease (PD), but the functional impact of Asian‐prevalent LRRK2 p.G2385R and p.R1628P variants remains unclear. Robust patient stratification and target engagement markers are needed for global LRRK2‐targeted trials ...
Tzi Shin Toh   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy